Active substance
Insulin recombinant human
- US FDA 4
- US price lines 8
- Safety 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| HUMULIN R | 100 UNITS/ML | injectable · injection | LILLY | Over-the-counter | 28 Oct 1982 |
| HUMULIN R PEN | 100 UNITS/ML | injectable · injection | LILLY | Over-the-counter | 28 Oct 1982 |
| NOVOLIN R | 100 UNITS/ML | injectable · injection | NOVO NORDISK INC | Over-the-counter | 25 Jun 1991 |
| AFREZZA | 4 UNITS/INH; 8 UNITS/INH; 12 UNITS/INH | powder · inhalation | MANNKIND | Prescription | 27 Jun 2014 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AFREZZA ((REGULAR INSULIN) 8 UNIT CARTRIDGE | $10.3754 | per EA | 23 Sep 2026 |
| US NADAC | AFREZZA (REGULAR INSULIN) 12 UNIT CARTRIDGE | $15.65297 | per EA | 20 May 2026 |
| US NADAC | AFREZZA (REGULAR INSULIN) 4 UNIT CARTRIDGE | $5.20552 | per EA | 23 Sep 2026 |
| US NADAC | AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT | $10.33288 | per EA | 23 Sep 2026 |
| US NADAC | AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT | $7.78053 | per EA | 23 Sep 2026 |
| US NADAC | AFREZZA (REGULAR INSULIN) 90-8 UNIT / 90-12 UNIT | $13.03769 | per EA | 1 Apr 2026 |
| US NADAC | NOVOLIN R 100 UNIT/ML FLEXPEN | $5.81495 | per ML | 23 Sep 2026 |
| US NADAC | NOVOLIN R 100 UNIT/ML VIAL | $4.62465 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 29 May 2026 AFREZZA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 27 Jun 2022 HUMULIN 70/30 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 27 Jun 2022 HUMULIN 70/30 PEN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 27 Jun 2022 HUMULIN R PEN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 15 Nov 2019 NOVOLIN 70/30 — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 15 Nov 2019 NOVOLIN R — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.